Cargando…

Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma

Combined inhibition of BRAF and MEK1/2 (CIBM) improves therapeutic efficacy of BRAF-mutant melanoma. However, drug resistance to CIBM is inevitable and the drug resistance mechanisms still remain to be elucidated. Here, we show that BMK1 pathway contributes to the drug resistance to CIBM. Considerin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Song, Chengli, Wang, Lina, Xu, Qiang, Wang, Kai, Xie, Dan, Yu, Zhe, Jiang, Kui, Liao, Lujian, Yates, John R., Lee, Jiing-Dwan, Yang, Qingkai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5384194/ https://www.ncbi.nlm.nih.gov/pubmed/28387310 http://dx.doi.org/10.1038/srep46244

Ejemplares similares

Corrigendum: Targeting BMK1 Impairs the Drug Resistance to Combined Inhibition of BRAF and MEK1/2 in Melanoma
por: Song, Chengli, et al.
Publicado: (2017)

Inhibition of BMK1 pathway suppresses cancer stem cells through BNIP3 and BNIP3L
por: Song, Chengli, et al.
Publicado: (2015)

IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma
por: Patel, Hima, et al.
Publicado: (2021)

Inhibition of BRAF and BRAF+MEK drives a metastatic switch in melanoma
por: Smalley, Keiran SM, et al.
Publicado: (2015)

BMK1 is involved in the regulation of p53 through disrupting the PML-MDM2 interaction
por: Yang, Q, et al.
Publicado: (2012)

Integrating BRAF/MEK inhibitors into combination therapy for melanoma
por: Smalley, K S M, et al.
Publicado: (2009)

BRAF and MEK inhibitors in the era of immunotherapy in melanoma patients
por: Mackiewicz, Jacek, et al.
Publicado: (2018)

TERT Expression Induces Resistance to BRAF and MEK Inhibitors in BRAF-Mutated Melanoma In Vitro
por: Delyon, Julie, et al.
Publicado: (2023)

RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2018)

A Predictive Model of Adaptive Resistance to BRAF/MEK Inhibitors in Melanoma
por: Ruiz, Emmanuelle M., et al.
Publicado: (2023)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for BRAF-Mutant Melanoma
por: Hamid, Omid, et al.
Publicado: (2019)

Correction to: RIP1 protects melanoma cells from apoptosis induced by BRAF/MEK inhibitors
por: Lei, Fu Xi, et al.
Publicado: (2019)

Triplet Therapy in Melanoma — Combined BRAF/MEK Inhibitors and Anti-PD-(L)1 Antibodies
por: Dixon-Douglas, Julia R., et al.
Publicado: (2022)

Comparison of responses of human melanoma cell lines to MEK and BRAF inhibitors
por: Stones, Clare J., et al.
Publicado: (2013)

Therapeutic Inhibitors against Mutated BRAF and MEK for the Treatment of Metastatic Melanoma
por: Ryu, Sunhyo, et al.
Publicado: (2017)

Bmk-1 regulates lifespan in Caenorhabditis elegans by activating hsp-16
por: Qian, Hong, et al.
Publicado: (2015)

Imaging markers of response to combined BRAF and MEK inhibition in BRAF mutated vemurafenib-sensitive and resistant melanomas
por: Acciardo, Stefania, et al.
Publicado: (2018)

Precision oncology for BRAF-mutant cancers with BRAF and MEK inhibitors: from melanoma to tissue-agnostic therapy
por: Gouda, M.A., et al.
Publicado: (2023)

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma
por: Wang, Beike, et al.
Publicado: (2021)

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
por: Yu, Qingliang, et al.
Publicado: (2019)

Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanoma
por: Pires da Silva, Ines, et al.
Publicado: (2022)

Risk factors for MEK-associated retinopathy in patients with advanced melanoma treated with combination BRAF and MEK inhibitor therapy
por: Booth, Andrew E. C., et al.
Publicado: (2020)

BRAF/MEK inhibitors promote CD47 expression that is reversible by ERK inhibition in melanoma
por: Liu, Fen, et al.
Publicado: (2017)

MEK + CDK4 a regimen for non-BRAF V6000 melanoma
por: Sosman, Jeff
Publicado: (2015)

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy
por: Reinhard, Raphael, et al.
Publicado: (2018)

Fibroblasts Influence Metastatic Melanoma Cell Sensitivity to Combined BRAF and MEK Inhibition
por: Morales, Delphine, et al.
Publicado: (2021)

BRAF and MEK inhibition in melanoma patients enables reprogramming of tumor infiltrating lymphocytes
por: Peiffer, Lukas, et al.
Publicado: (2020)

Long-term survival of patients with advanced melanoma treated with BRAF-MEK inhibitors
por: Ismail, Rawa K., et al.
Publicado: (2022)

Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma
por: Hui, Caressa, et al.
Publicado: (2022)

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial
por: Ascierto, Paolo A., et al.
Publicado: (2023)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
por: Pisanu, Maria Elena, et al.
Publicado: (2018)

BmK-YA, an Enkephalin-Like Peptide in Scorpion Venom
por: Zhang, Yan, et al.
Publicado: (2012)

Tumor Cell Resistance to the Inhibition of BRAF and MEK1/2
por: Chen, Wenjing, et al.
Publicado: (2023)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
por: Huynh, Sandra, et al.
Publicado: (2020)

Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors
por: Martinez, Ramon, et al.
Publicado: (2022)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
por: Spagnolo, Francesco, et al.
Publicado: (2021)

Lessons from clinical trials on triple combination of immune checkpoint inhibitors and BRAF/MEK inhibitors in BRAF-mutant melanoma
por: Maeda, Takuya, et al.
Publicado: (2023)

Tumoral melanosis associated with combined BRAF/MEK inhibition (dabrafenib/trametinib) in metastatic melanoma
por: Laino, Antonia, et al.
Publicado: (2018)

Combinatorial Therapies to Overcome BRAF/MEK Inhibitors Resistance in Melanoma Cells: An in vitro Study
por: Pópulo, Helena, et al.
Publicado: (2021)

Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
por: Deng, Xianming, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_8i7a0uoam52nme3hgm0dbi0a14